<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Colomb Med (Cali)</journal-id>
<journal-id journal-id-type="publisher-id">cm</journal-id>
<journal-title-group>
<journal-title>Colombia Médica : CM</journal-title>
</journal-title-group>
<issn pub-type="ppub">0120-8322</issn>
<issn pub-type="epub">1657-9534</issn>
<publisher>
<publisher-name>Universidad del Valle</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29299012</article-id>
<article-id pub-id-type="pmc">5687867</article-id>
<article-id pub-id-type="doi">10.25100/cm.v48i3.3019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Tremor-Ataxia syndrome and primary ovarian insufficiency in an<bold><italic>FMR1</italic></bold> premutation carrier</article-title>
<trans-title-group xml:lang="es">
<trans-title>Síndrome de Tremor Ataxia y falla ovárica prematura en portadora de la premutación del gen <bold><italic>FMR1</italic></bold></trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Saldarriaga-Gil</surname>
<given-names>Wilmar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Guerrero</surname>
<given-names>Tatiana</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fandiño-Losada</surname>
<given-names>Andres</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramirez-Cheyne</surname>
<given-names>Julian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label> Grupo de investigación MACOS, Departamento Morfología, Facultad de Salud Universidad del Valle, Cali, Colombia.</aff>
<aff id="aff2">
<label>2</label> Departamento de Medicina y Cirugía, Facultad de Salud, Universidad del Valle, Cali, Colombia.</aff>
<aff id="aff3">
<label>3</label> Escuela de Salud Pública, Universidad del Valle, Cali, Colombia.</aff>
<author-notes>
<corresp id="c1">Wilmar Saldarriaga Gil. Carrera 37 # 1oeste-45, Apto 1203B. Unidad Mirador Avalon. Cali, Colombia. Phone: +57 2 316 446 1596. E-mail: <email>wilmar.saldarriaga@correounivalle.edu.co</email></corresp>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2017-06-30" publication-format="electronic">
<day>30</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date date-type="collection" publication-format="electronic">
<season>Jul-Sep</season>
<year>2017</year>
</pub-date>
<volume>48</volume>
<issue>3</issue>
<fpage>148</fpage>
<lpage>151</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>6</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Universidad del Valle</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>This article is distributed under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<abstract>
<title>Abstract</title>
<sec>
<title>Introduction:</title>
<p> The <italic>FMR1</italic> gene has four allelic variants according to the number of repeats of the CGG triplet. Premutation carriers with between 55 and 200 repeats are susceptible to developing pathologies such as tremor and ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI) syndrome. </p>
</sec>
<sec>
<title>Case description:</title>
<p> The patient was a 53-year-old female farmer with severe tremor in the upper limbs at rest that worsens with movement, tremor in the jaw and tongue, and generalized cerebral atrophy. She is a carrier of the <italic>FMR1</italic> premutation diagnosed by PCR and Southern Blot, complying with the clinical and radiological criteria of FXTAS, and in addition, has a history of vagal symptoms suggestive of ovarian failure and menstrual cycle disorders that led to hysterectomy at age 33 and was subsequently diagnosed with FXPOI. </p>
</sec>
<sec>
<title>Conclusion: </title>
<p>An unusual case of FXTAS and FXPOI complying with clinical and radiological criteria is reported in a premutation carrier of the <italic>FMR1</italic> gene<italic>.</italic>
</p>
</sec>
</abstract>
<trans-abstract xml:lang="es">
<title>Resumen</title>
<sec>
<title>Introducción: </title>
<p>el gen <italic>FMR1</italic> tiene cuatro variantes alélicas según el número de repeticiones de la tripleta CGG. Los portadores de la premutación con un número entre 55 y 200 repeticiones son susceptibles de desarrollar patologías como el síndrome de temblor y ataxia (FXTAS) y síndrome de falla ovárica prematura (FXPOI) asociados al X frágil. </p>
</sec>
<sec>
<title>Descripción del caso: </title>
<p>Mujer de 53 años, agricultora, con temblor severo en miembros superiores en reposo que empeora con el movimiento, temblor en mandíbula y lengua, atrofia cerebral generalizada, portadora de la premutación del gen <italic>FMR1</italic> diagnosticada por PCR y Southern Blot, cumpliendo con criterios clínicos y radiológicos de FXTAS; ademas, historia de síntomas vagales sugestivos de falla ovárica y trastornos del ciclo menstrual que llevaron a histerectomía a los 33 años, haciendose diagnóstico FXPOI. </p>
</sec>
<sec>
<title>Conclusión:</title>
<p> Se reporta un caso inusual en portadoras de la premutación del gen <italic>FMR1,</italic> con criterios clínicos y radiológicos de FXTAS y FXPOI. </p>
</sec>
</trans-abstract>
<kwd-group>
<title>Key words:</title>
<kwd>Fragile X Tremor Ataxia Syndrome</kwd>
<kwd>Ataxia/complications</kwd>
<kwd>Ataxia/diagnosis</kwd>
<kwd>Ataxia/genetics</kwd>
<kwd>FXPOI</kwd>
<kwd>FXTAS</kwd>
<kwd><italic>FMR1</italic>gen</kwd>
</kwd-group>
<kwd-group xml:lang="es">
<title>Palabras clave: </title>
<kwd>síndrome de temblor y ataxia X fragil</kwd>
<kwd>complicaciones/ataxia</kwd>
<kwd>diagnostico/ataxia</kwd>
<kwd>genetica/ataxia</kwd>
<kwd>FXPOI</kwd>
<kwd>FXTAS</kwd>
<kwd>gen <italic>FMR1</italic></kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="19"></ref-count>
<page-count count="04"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>The FMR1 (Fragile X Mental Retardation 1 Gene) gene, with locus Xq27.3, has 17 exons spanning 38 kb, OMIM * 309550 <xref ref-type="bibr" rid="B1">1</xref>. This gene is characterized by presenting variable numbers of nucleotide triplet repeats of cytosine-guanine-guanine (CGG) in the 5' untranslated region (UTR5'). According to the number of triplets, four allelic variants occur: full mutation (MC) (&gt;200 triplets), premutated (PM) (55-200), gray area (ZG) (45-54), and normal (&lt;45) <xref ref-type="bibr" rid="B2">2</xref>.</p>
<p>The carriers of the premutation have a variable phenotype and incomplete penetrance completely different than those who have CM and are affected by Fragile X syndrome (FXS) <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>.</p>
<p>Pathologies found in carriers have been referred to as FRAXopathies, and the most well-known are tremor and ataxia associated with FXS (Fragile X Tremor Ataxia Syndrome; FXTAS) and primary ovarian insufficiency syndrome associated with FXS (FXPOI) <xref ref-type="bibr" rid="B5">5</xref>. The diagnosis of these entities is made mainly through clinical findings and specific signs in nuclear magnetic resonance (MRI) of the brain <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>. Environmental agents have been associated with the early onset and greater severity of symptoms <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>.</p>
<p>The objective of this article is to contribute to the literature by reporting a rare case of FXTAS and FXPOI in a carrier of FMR1 premutation with the appearance of symptoms at an early age and severe symptomatology. This is the first report of this association in Colombia.</p>
</sec>
<sec>
<title>Case description</title>
<p>The patient is originally from a Colombian population north of Valle del Cauca, a region with a high prevalence of premutation and full mutation of the FMR1 gene.</p>
<p>The patient is a 53-year-old woman, a farmer, with a 4-year history of distal tremor at rest that worsens with movement, with a greater involvement of the upper limbs, that has become increasingly severe. In the last year, the tremor involved the mandibular region and the tongue. Therefore, the patient repeatedly consulted a physician; electrolyte and thyroid function studies were performed, and cerebral structural alterations were measured by computerized axial tomography. All results were within normal limits. However, due to the tremor's worsening, a contrast-enhanced brain MRI was performed and showed significant cortical and subcortical atrophy, with greater frontotemporal involvement, and an increase in the size of the ventricular system, markedly in the third ventricle <xref ref-type="fig" rid="f1">Fig. 1</xref>. Other findings were not significant.</p>
<p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Magnetic resonance of the brain with gadolinium. Contrast-enhanced brain MRI shows marked cortical and subcortical atrophy in the frontal region plus dilation of the ventricular system. </title></caption><graphic xlink:href="1657-9534-cm-48-03-00148-gf2"></graphic></fig>
</p>
<p>Subsequently, a molecular study was performed for the quantification of FMR1 gene triplets with PCR using a triple primer, including a CGG-specific primer and Southern Blot. Thirty and 82 repeats were found in each allele. </p>
<p>Personal pathological antecedents included convulsive syndrome in childhood that was spontaneously resolved at 14 years old; medically managed bilateral carpal tunnel; a gestational formula G5P3C2V2Mo3; and irregular menstrual cycles characterized by persistent polymenorrhea and metrorrhagia, without improvement despite medical management that forced a hysterectomy at the age of 33 years. The living children were studied, and none had PM or MC of the FMR1 gene. In the year prior to hysterectomy and up to 2 years later, she reported perimenopausal symptoms such as hot flashes, profuse night sweats, persistent headache, and vaginal dryness. </p>
<p>At the time of the physical examination, there was a tremor at rest that involved the upper limbs, the jaw and the tongue, which worsened during activity. In spite of the limitation for performing cerebellar tests imposed by the tremor, no alterations in gait pattern or other signs of cerebellar ataxia were documented. The Fahn-Tolosa-Marín tremor rating scale <xref ref-type="bibr" rid="B6">6</xref> was applied to obtain an objective approximation to the findings of the physical examination, and a 15% severity of the involvement was measured <xref ref-type="table" rid="t1">Table 1</xref>.</p>
<p>Another relevant element found in the physical examination was the presence of neuropathy in the four extremities caused by the alteration of superficial sensitivity with the presence of hypoesthesia and paresthesia.</p>
<p>During the interview, manifestations of anxiety with affective modulation were observed. The GAD-7 Scale <xref ref-type="bibr" rid="B7">7</xref> was then applied with a result that suggested a moderate generalized anxiety disorder. </p>
<p>In addition, an evaluation of the patient's cognitive status was Fahn-Tolosa-Marín performed through the Mini-Mental test in which 25 points out of 30 were obtained, which is suggestive of a pathology.</p>
<p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Fahn-Tolosa-Marín tremor rating scale applied to the patient. </title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="4"/><col span="4"/></colgroup><tbody><tr><td align="left" colspan="1" rowspan="1">Location of tremor</td><td align="left" colspan="1" rowspan="1">Lips</td><td align="left" colspan="1" rowspan="1">Jaw</td><td align="left" colspan="1" rowspan="1">Upper limbs</td></tr><tr><td align="left" colspan="1" rowspan="1">Classification</td><td align="left" colspan="1" rowspan="1">Resting</td><td align="left" colspan="1" rowspan="1">Resting</td><td align="left" colspan="1" rowspan="1">Resting and Postural</td></tr></tbody><tbody><tr><td align="center" colspan="4" rowspan="1">Assessment of tremor in upper limbs</td></tr><tr><td align="left" colspan="1" rowspan="1">Intensity</td><td align="left" colspan="1" rowspan="1">Marked</td><td align="left" colspan="1" rowspan="1">Marked</td><td align="left" colspan="1" rowspan="1">Marked</td></tr><tr><td align="left" colspan="1" rowspan="1">Writing</td><td align="left" colspan="3" rowspan="1">Minimally abnormal</td></tr><tr><td align="left" colspan="1" rowspan="1">When outlining</td><td align="left" colspan="3" rowspan="1">Moderate or crosses lines frequently</td></tr><tr><td align="left" colspan="1" rowspan="1">When pouring</td><td align="left" colspan="3" rowspan="1">More careful than a person without tremors, but without spilling water </td></tr></tbody><tbody><tr><td align="center" colspan="4" rowspan="1">Functional disability that causes tremor</td></tr><tr><td align="left" colspan="1" rowspan="1">When talking</td><td align="left" colspan="3" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">Eating</td><td align="left" colspan="3" rowspan="1">Slightly abnormal; can bring food to the mouth and only spills rarely</td></tr><tr><td align="left" colspan="1" rowspan="1">Bring liquids to the mouth</td><td align="left" colspan="3" rowspan="1">Slightly abnormal; can use the spoon, but not if it is completely full</td></tr><tr><td align="left" colspan="1" rowspan="1">Hygiene</td><td align="left" colspan="3" rowspan="1">Slightly abnormal; does everything, but carefully</td></tr><tr><td align="left" colspan="1" rowspan="1">Dress</td><td align="left" colspan="3" rowspan="1">Slightly abnormal; able to do everything, but carefully</td></tr><tr><td align="left" colspan="1" rowspan="1">Write</td><td align="left" colspan="3" rowspan="1">Slightly abnormal; legible, able to write long letters</td></tr><tr><td align="left" colspan="1" rowspan="1">Work</td><td align="left" colspan="3" rowspan="1">Does not interfere with work</td></tr><tr><td align="left" colspan="1" rowspan="1">Overall rating by the examiner</td><td align="left" colspan="3" rowspan="1">Moderate disability (25-49%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Overall rating by the patient</td><td align="left" colspan="3" rowspan="1">Mild disability (1-24%)</td></tr><tr><td align="left" colspan="3" rowspan="1">Total score </td><td align="center" colspan="1" rowspan="1">15%</td></tr></tbody></table></table-wrap>
</p>
<p>The testing was assessed by a neurologist who initiated treatment with propanolol for tremor management and also by a psychiatrist who considered psychotherapeutic management without the need for medication at that time. </p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The prevalence of FMR1 premutation is 11.7 per 10,000 males (95% CI: 6.0-18.7) and 34.4 per 10,000 females (95% CI: 6.3-83.3), corresponding to 1 for every 855 males and 1 for every 291 females <xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>. There are no data on the prevalence of allelic variants of the FMR1 gene in Columbia. </p>
<p>The carriers of the premutation can develop pathologies called FRAXopathy, such as FXTAS and FXPOI <xref ref-type="bibr" rid="B2">2</xref>. In addition, adults with and without FXTAS or FXPOI are at greater risk than the general population for presenting with affective problems, depression, anxiety, obsessive compulsive disorder, sleep disturbances, sleep apnea, neuropathies, psychiatric disorders, hypertension, migraine, fibromyalgia, and disorders of the thyroid gland <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>. Additionally, in childhood, greater risk of anxiety, attention deficit and hyperactivity, autistic spectrum disorders and seizures can be observed in carriers <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B13">13</xref>.</p>
<p>The phenotype of those affected by the MC of the FMR1 gene is completely different and does not have the classic features of FXS such as mild to moderate intellectual disability (ID), autistic spectrum disorders, elongated face, prognathism, large winged ears, joint hypermobility, macroorchidism, language deficit, anxiety and aggression. In females, the phenotype is usually less severe <xref ref-type="bibr" rid="B11">11</xref>.</p>
<p>FXPOI is found in 20% of premutation carriers. Menstrual bleeding often stops for a year before the age of 40, which is a diagnosis of primary ovarian insufficiency. This frequency is increased 20-fold when compared to the general population, where primary ovarian insufficiency is approximately 1% <xref ref-type="bibr" rid="B14">14</xref>. In addition, ovarian failure has been reported to be higher in carriers at all ages at which studies have been performed: 1.4% at age 18 years, and 3.0% at age 29 years versus 1 in 1,000 in the general population; in addition, carriers have menopause at an early age after 40 years <xref ref-type="bibr" rid="B14">14</xref>. In these females, there are other signs and secondary symptoms such as hormonal alterations with elevated levels of FSH and low levels of estradiol, irregular menstrual cycles, perimenopausal symptoms and decreased fertility <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>. </p>
<p>In the patient reported here, the association of irregular menstrual cycles that led to hysterectomy at age 33, vagal symptoms (related to menopause) and the finding of FMR1 premutation led us to conclude that the patient had primary ovarian insufficiency and FXPOI.</p>
<p>FXTAS is a progressive neurodegenerative disorder characterized by neurological deficits that include progressive intention tremor, cerebellar ataxia, cognitive deficit, parkinsonism, neuropathies, autonomic dysfunction and dementia. This syndrome occurs in 40% of male carriers at age 60 and in 75% at age 80 and occurs in 20% of females <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B9">9</xref>. In the general population, the estimated prevalence is 1 in 4,000 males older than 55 years and 1 in 7,800 in females <xref ref-type="bibr" rid="B3">3</xref>.</p>
<p>In FXTAS, the alteration in the FMR1 gene does not silence the FMR1 gene as in those affected by the FXS in which the FMRP (Fragile X Mental Retardation Protein) is diminished or absent <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B17">17</xref>. On the contrary, there is overexpression, producing between 2-8 times the normal amount of FMR1 mRNA <xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>. The latter would be responsible for neuronal toxicity and lead to late presentation of neurodegenerative disorders <xref ref-type="bibr" rid="B4">4</xref>. In FXPOI, it has not been possible to demonstrate how the mRNA level affects the hypothalamus-pituitary-gonad axis or the ovary directly <xref ref-type="bibr" rid="B16">16</xref>. </p>
<p>The diagnosis of FXTAS in FMR1 premutation carriers combines clinical, radiological, neuroimaging and pathological criteria <xref ref-type="bibr" rid="B12">12</xref>. The major criteria are intention tremor, cerebellar ataxia, cognitive impairment and hyperintensity of the middle cerebellar peduncle, and rounded intranuclear inclusions typical of FXTAS in neurons and astrocytes. Minor criteria include short-term memory problems of moderate to severe intensity, neuropathy, deficits in executive functions, parkinsonism, generalized cerebral atrophy, and white matter disease in the brain or cerebellum. The symptoms are less severe in females <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B18">18</xref>.</p>
<p>For a definitive diagnosis of FXTAS, it is necessary to have two major criteria: a major clinical criterion plus a major radiological criterion or pathological criterion; the presence of two major clinical criteria or a minor clinical criterion plus a minor radiological criterion make a probable diagnosis. Finally, a possible diagnosis of FXTAS is based on the presence of a minor clinical criterion and a minor clinical criterion <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>.</p>
<p>The diagnosis of FXTAS in the patient reported here was made by having two major clinical criteria: intension tremor of severe intensity and sustained cognitive impairment demonstrated by a lower than expected score in the Mini-Mental test, and the minor radiological criterion being generalized and marked cortical atrophy in the frontal region. In addition, generalized anxiety was noted, and neuropathy was present as carpal tunnel syndrome. The severity of the symptoms and the early age of the FXTAS make the case infrequent and of poor prognosis.</p>
<p>However, in this patient, the age of onset of FXPOI at approximately 33 years, the age of onset of FXTAS symptoms before age 50, the severity of symptoms such as intention tremor that prevents her from performing activities of daily living, mandibular tremor, cognitive deficits, anxiety and generalized cortical atrophy make us consider that this is a very rare case, not only because of the low prevalence of FXTAS in females but also because of the poor presentation of FXTAS and FXPOI simultaneously, with a natural history of unusual disease. </p>
<p>Treatment of FXTAS is mainly symptomatic, with therapeutic options that seek to alleviate neuromotor and psychiatric symptoms, with beta blockers, such as propanolol, being the most used for the relief of essential tremor, followed by anticonvulsants. Patients with ataxia have shown improvement with the use of memantine <xref ref-type="bibr" rid="B19">19</xref>. Selective serotonin reuptake inhibitors (SSRIs) indicated in many of the mixed disorders associated with anxiety or depression are useful in patients with FXTAS. Physical and recreational activities and folate and vitamin B12 supplementation are used to maintain motor and cognitive abilities and reduce brain atrophy <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B19">19</xref>. Descriptions of the FRAXopathies <xref ref-type="bibr" rid="B4">4</xref> have been relatively recent and access to molecular tests is limited in our environment. We suggest that patients with primary ovarian insufficiency, tremor and/or ataxia should be suspected of having premutation of the FMR1 gene. The probability of diagnosis is increased when there is a specific family history of FXS or intellectual disability of unknown origin and also when specific criteria are found in brain images. The diagnosis should be discarded or confirmed with molecular tests such as PCR and Southern Blot specific for the FMR1 gene <xref ref-type="bibr" rid="B2">2</xref>.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>We present a patient with clinical and radiological criteria indicating FXTAS and FXPOI with the appearance of symptoms at an early age and severe symptomatology, showing a natural history of the rare disease in carriers of FMR1 gene premutation.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="webpage">
<person-group person-group-type="author">
<collab>Online Mendelian Inheritance in Man</collab>
</person-group>
<source/>An Online Catalog of Human Genes and Genetic Disorders. Entry - # 300624 - Fragile X Mental Retardation Syndrome
          <date-in-citation content-type="access-date" iso-8601-date="2014-08-31">2014 Aug 31</date-in-citation>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.omim.org/entry/300624">http://www.omim.org/entry/300624</ext-link></comment>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saldarriaga</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>González-Teshima</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Forero-Forero</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Ayala-Zapata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Síndrome de X Frágil</article-title>
<source/>Colomb Med (Cali)
          <year>2014</year>
<volume>45</volume>
<issue>4</issue>
<fpage>190</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">25767309</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management</article-title>
<source/>Nat Rev Neurol
          <year>2016</year>
<volume>12</volume>
<issue>7</issue>
<fpage>403</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">27340021</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="editor">
<name>
<surname>Pirozzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tabolacci</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The FRAXopathies: Definition, overview, and update</article-title>
<source/>Am J Med Genet A
          <year>2011</year>
<volume>155A</volume>
<issue>8</issue>
<fpage>1803</fpage>
<lpage>1816</lpage>
<pub-id pub-id-type="pmid">21739597</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saldarriaga</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>González</surname>
<given-names>TLY</given-names>
</name>
<name>
<surname>Isaza</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Polyak</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Phenobarbital use and neurological problems in FMR1 premutation carriers</article-title>
<source/>Neurotoxicology
          <year>2016</year>
<volume>53</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">26802682</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Faher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tolosa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>C</given-names>
</name>
</person-group>
<chapter-title>Clinical rating scale for tremor</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Jankovic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tolosa</surname>
<given-names>E</given-names>
</name>
</person-group>
<source/>Parkinson´s Disease and Movement Disorder
          <publisher-loc>Baltimore</publisher-loc>
<publisher-name>Urban &amp; Schwarzenberg</publisher-name>
<year>1988</year>
<fpage>225</fpage>
<lpage>234</lpage>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spitzer</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Kroenke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>JBW</given-names>
</name>
<name>
<surname>Löwe</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>A brief measure for assessing generalized anxiety disorder The GAD-7</article-title>
<source/>Arch Internal Med
          <year>2006</year>
<volume>166</volume>
<issue>10</issue>
<fpage>1092</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="pmid">16717171</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rivero-Arias</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Angelov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fotheringham</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Leal</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Epidemiology of fragile X syndrome A systematic review and meta-analysis</article-title>
<source/>Am J Med Genet A
          <year>2014</year>
<volume>164A</volume>
<issue>7</issue>
<fpage>1648</fpage>
<lpage>1658</lpage>
<pub-id pub-id-type="pmid">24700618</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigsby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brega</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning</article-title>
<source/>Clin Neuropsychol
          <year>2016</year>
<volume>30</volume>
<issue>6</issue>
<fpage>944</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">27355103</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordeiro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Abucayan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Anxiety disorders in fragile X premutation carriers Preliminary characterization of probands and non-probands</article-title>
<source/>Intractable Rare Dis Res
          <year>2015</year>
<volume>4</volume>
<issue>3</issue>
<fpage>123</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">26361563</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigsby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brega</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Goodrich</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning</article-title>
<source/>Clin Neuropsychol
          <year>2016</year>
<volume>30</volume>
<issue>6</issue>
<fpage>944</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">27355103</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lozano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eldeeb</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Aging in Fragile X Premutation Carriers</article-title>
<source/>Cerebellum
          <year>2016</year>
<volume>15</volume>
<issue>5</issue>
<fpage>587</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="pmid">27334385</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chonchaiya</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Au</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Laird</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder</article-title>
<source/>Hum Genet
          <year>2012</year>
<volume>131</volume>
<issue>4</issue>
<fpage>581</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="pmid">22001913</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welt</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Evidence of early ovarian aging in fragile X premutation carriers</article-title>
<source/>J Clin Endocrinol Metab
          <year>2004</year>
<volume>89</volume>
<issue>9</issue>
<fpage>4569</fpage>
<lpage>4574</lpage>
<pub-id pub-id-type="pmid">15356064</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheeler</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Raspa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Health and reproductive experiences of women with an FMR1 premutation with and without fragile X premature ovarian insufficiency</article-title>
<source/>Front Genet
          <year>2014</year>
<volume>5</volume>
<fpage>300</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">25250044</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sherman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>LM</given-names>
</name>
</person-group>
<chapter-title>Clinical manifestation and management of FXPOI</chapter-title>
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>DA</given-names>
</name>
</person-group>
<source/>FXTAS, FXPOI, and Other Premutation Disorders
          <edition>Second</edition>
<year>2016</year>
<publisher-loc>Switzerland</publisher-loc>
<publisher-name>Springer</publisher-name>
<fpage>199</fpage>
<lpage>224</lpage>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sethna</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>From FMRP function to potential therapies for fragile X syndrome</article-title>
<source/>Neurochem Res
          <year>2014</year>
<volume>39</volume>
<issue>6</issue>
<fpage>1016</fpage>
<lpage>1031</lpage>
<pub-id pub-id-type="pmid">24346713</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Usdin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hukema</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>SL</given-names>
</name>
</person-group>
<chapter-title>Model systems for understanding FXPOI</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>DA</given-names>
</name>
</person-group>
<source/>FXTAS, FXPOI, and Other Premutation Disorders
          <edition>second</edition>
<year>2016</year>
<publisher-loc>Switzerland</publisher-loc>
<publisher-name>Springer</publisher-name>
<fpage>225</fpage>
<lpage>240</lpage>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hager- Man</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Mov Disord
          <year>2006</year>
<volume>21</volume>
<issue>10</issue>
<fpage>1741</fpage>
<lpage>1744</lpage>
<pub-id pub-id-type="pmid">16773616</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<sub-article article-type="translation" id="s1" xml:lang="es">
<front-stub>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reporte de Caso</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Síndrome de Tremor Ataxia y falla ovárica prematura en portadora de la premutación del gen <bold><italic>FMR1</italic></bold></article-title>
</title-group>
</front-stub>
<body>
<sec>
<title>Introducción</title>
<p>El gen FMR1 (Fragile X Mental Retardation 1 Gene), con locus Xq27.3, tiene 17 exones que abarcan 38 Kb, OMIM *309550 <xref ref-type="bibr" rid="B1">1</xref>; este gen se caracteriza por presentar en la región no traducida 5´ (UTR5´), números variables de repeticiones de la tripleta de nucleótidos Citocina Guanina Guanina CGG; según el número de tripletas se producen cuatro variantes alélicas: mutación completa (MC) (&gt;200), premutación (PM) (55-200), zona gris (ZG) (45-54), normal (&lt;45) <xref ref-type="bibr" rid="B2">2</xref>.</p>
<p>Los portadores de la premutación tienen un fenotipo variable y de penetrancia incompleta completamente diferente a quienes tienen la MC y son afectados por el síndrome X Frágil (SXF) <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>.</p>
<p>A las patologías encontradas en portadores se les ha denominado FRAXOPATIAS y las más conocidas son el síndrome de temblor y ataxia asociado al SXF (FXTAS, abreviado de las palabras en inglés Fragile X Tremor Ataxia Syndrome) y el síndrome de falla ovárica primaria asociado al SXF (FXPOI) <xref ref-type="bibr" rid="B5">5</xref>. El diagnostico de estas entidades se hace principalmente a través de hallazgos clínicos y signos específicos en resonancia nuclear magnética (RMN) de cerebro <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>. Agentes ambientales se han asociado con la aparición temprana y mayor severidad de los síntomas <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>.</p>
<p> El objetivo de este artículo es aportar a la literatura un raro caso de FXTAS y FXPOI en una portadora de la premutación del gen FMR1, con aparición de los síntomas a edad temprana y sintomatología severa, siendo este el primer reporte de esta asociación en Colombia.</p>
</sec>
<sec>
<title>Descripción del caso</title>
<p>La paciente es originaria y procedente de una población Colombiana al norte del Valle del Cauca, región con elevada prevalencia de premutación y mutación completa del gen FMR1.</p>
<p>Mujer de 53 años, agricultora, con una historia de 4 años de temblor distal en reposo que empeora con el movimiento, con un mayor compromiso de los miembros superiores, el cual se hace cada vez más severo; en el último año, el temblor comprometió la región mandibular y la lengua. Por lo anterior, ella consultó en repetidas ocasiones y se realizaron estudios de electrolitos, función tiroidea y alteraciones estructurales cerebrales mediante una tomografía axial computarizada, todos los resultados dentro de los límites normales. Sin embargo, por empeoramiento del temblor le realizaron RMN contrastada de cerebro, la cual mostró una atrofia cortical y subcortical significativa, con un mayor compromiso frontotemporal, un aumento del tamaño del sistema ventricular, marcado en el tercer ventrículo; sin otros hallazgos <xref ref-type="fig" rid="f2">Fig. 1</xref>.</p>
<p>
<fig id="f2" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Resonancia Magnética de Cerebro con gadolinio. La RMN de cerebro con contraste muestra atrofia cortical y subcortical marcada en la región frontal más dilatación del sistema ventricular. </title></caption><graphic xlink:href="1657-9534-cm-48-03-00148-gf2"></graphic></fig>
</p>
<p>Posteriormente, se le realizó un estudio molecular para la cuantificacion de las tripletas del gen FMR1 con PCR, usando un triple cebador, incluyendo un cebador especifico para CGG y Southern Blot. Se encontraron 30 y 82 repeticiones en cada alelo. </p>
<p>Con los antecedentes patológicos personales que incluyeron: síndrome convulsivo en la infancia que se resolvió espontáneamente a los 14 de años, túnel de carpo bilateral en manejo médico; una fórmula gestacional G5P3C2V2Mo3; los ciclos menstruales irregulares caracterizados por polimenorreas y metrorragias persistentes, sin mejoría a pesar del manejo médico, que obligaron a la realización de una histerectomía a la edad de 33 años. Los hijos vivos fueron estudiados y ninguno presentó PM o MC del gen FMR1. Refirió, en el año previo a la histerectomía y hasta dos años después, síntomas perimenopáusicos como oleadas de calor, sudoración nocturna profusa, cefalea persistente y sequedad vaginal. </p>
<p>Al momento del examen físico se evidenció temblor en reposo que compromete los miembros superiores, la mandíbula y la lengua, que empeora durante la actividad; a pesar de la limitación para la realización de pruebas cerebelosas impuestas por el temblor, no se documentaron alteraciones del patrón de marcha, ni otros signos de ataxia cerebelosa. Buscando una aproximación objetiva a los hallazgos del examen físico se aplicó la Escala de Temblor de Fahn, Tolosa y Marín <xref ref-type="bibr" rid="B6">6</xref>, obteniendo un 15% de severidad del compromiso <xref ref-type="table" rid="t2">Tabla 1</xref>.</p>
<p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Tabla 1</label><caption><title>Escala de Temblor de Fahn, Tolosa y Marín aplicada a la paciente. </title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="4"/><col span="4"/></colgroup><tbody><tr><td align="justify" colspan="1" rowspan="1">Localización del temblor</td><td align="justify" colspan="1" rowspan="1">Labios</td><td align="justify" colspan="1" rowspan="1">Mandíbula</td><td align="justify" colspan="1" rowspan="1">Miembros superiores</td></tr><tr><td align="justify" colspan="1" rowspan="1">Clasificación</td><td align="justify" colspan="1" rowspan="1">Reposo</td><td align="justify" colspan="1" rowspan="1">Reposo</td><td align="justify" colspan="1" rowspan="2">Reposo y Postural</td></tr></tbody><tbody><tr><td align="center" colspan="4" rowspan="1">Valoración del temblor en miembros superiores</td></tr><tr><td align="justify" colspan="1" rowspan="1">Intensidad</td><td align="justify" colspan="1" rowspan="1">Marcada</td><td align="justify" colspan="1" rowspan="1">Marcada</td><td align="justify" colspan="1" rowspan="1">Marcada</td></tr><tr><td align="justify" colspan="1" rowspan="1">Escritura</td><td align="justify" colspan="3" rowspan="1">Mínimamente anormal</td></tr><tr><td align="justify" colspan="1" rowspan="1">Al delinear</td><td align="justify" colspan="3" rowspan="1">Moderado o cruza líneas frecuentemente</td></tr><tr><td align="justify" colspan="1" rowspan="1">Al verter</td><td align="justify" colspan="3" rowspan="1">Más cuidadoso que una persona sin temblor, pero sin derramar agua</td></tr></tbody><tbody><tr><td align="center" colspan="4" rowspan="1">Incapacidad funcional que genera el temblor</td></tr><tr><td align="justify" colspan="1" rowspan="1">Al hablar</td><td align="justify" colspan="3" rowspan="1">No</td></tr><tr><td align="justify" colspan="1" rowspan="1">Al comer</td><td align="justify" colspan="3" rowspan="1">Levemente anormal. Puede llevar los alimentos a la boca y sólo los derrama raramente</td></tr><tr><td align="justify" colspan="1" rowspan="1">Llevar líquidos a la boca</td><td align="justify" colspan="3" rowspan="1">Levemente anormal. Puede usar la cuchara, pero no si está completamente llena</td></tr><tr><td align="justify" colspan="1" rowspan="1">Higiene</td><td align="justify" colspan="3" rowspan="1">Levemente anormal. Lo realiza todo, pero cuidadosamente</td></tr><tr><td align="justify" colspan="1" rowspan="1">Vestirse</td><td align="justify" colspan="3" rowspan="1">Levemente anormal. Capaz de hacerlo todo, pero de una forma cuidadosa </td></tr><tr><td align="justify" colspan="1" rowspan="1">Escribir</td><td align="justify" colspan="3" rowspan="1">Levemente anormal. Legible, capaz de escribir cartas largas</td></tr><tr><td align="justify" colspan="1" rowspan="1">Trabajo</td><td align="justify" colspan="3" rowspan="1">No interfiere con el trabajo </td></tr><tr><td align="justify" colspan="1" rowspan="1">Valoración global del examinador</td><td align="justify" colspan="3" rowspan="1">Incapacidad moderada (25-49%) </td></tr><tr><td align="justify" colspan="1" rowspan="1">Valoración global del paciente</td><td align="justify" colspan="3" rowspan="1">Incapacidad leve (1-24%)</td></tr><tr><td align="justify" colspan="3" rowspan="1">Puntaje total</td><td align="center" colspan="1" rowspan="1">15%</td><td align="center" colspan="1" rowspan="1">
</td></tr></tbody></table></table-wrap>
</p>
<p>Otro elemento relevante encontrado en el examen físico fue la presencia de una neuropatía en las cuatro extremidades, causada por la alteración de la sensibilidad superficial, con la presencia de hipoestesia y parestesias.</p>
<p>Durante la entrevista con modulación del afecto, se observaron manifestaciones de ansiedad. Se aplicó entonces, la Escala GAD-7 <xref ref-type="bibr" rid="B7">7</xref> con un resultado que sugirió un trastorno de ansiedad generalizada moderado. </p>
<p>Además, se realizó una evaluación del estado cognitivo de la paciente a través del test de MINIMENTAL, en el cual se obtuvieron 25 puntos de 30 posibles, siendo este resultado sugestivo de una patología.</p>
<p>Fue valorada por neurología quien inició un tratamiento con propanolol para manejo del temblor y también por psiquiatría quien consideró un manejo psicoterapéutico sin necesidad de medicación en ese momento. </p>
</sec>
<sec>
<title>Discusión</title>
<p>La prevalencia de la premutación del gen FMR1 es de 11.7 por cada 10,000 hombres (IC 95%: 6.0-18.7) y 34.4 por cada 10,000 mujeres (IC 95%: 6.3-83.3), correspondiendo a 1 por cada 855 hombres y 1 por cada 291 mujeres <xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>. En Colombia no hay datos de la prevalencia de las variantes alélicas del gen FMR1. </p>
<p>Los portadores de la premutación pueden desarrollar patologías denominadas FRAXOPATIAS, como FXTAS y FXPOI <xref ref-type="bibr" rid="B2">2</xref>. Además, los adultos con y sin FXTAS o FXPOI presentan más riesgo que la población general, de presentar problemas afectivos, depresión, ansiedad, trastorno obsesivo compulsivo, alteraciones del sueño, apnea del sueño, neuropatías, trastornos psiquiátricos, hipertensión, migraña, fibromialgia, y trastornos de la glándula tiroides <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>. Igualmente en la infancia se puede observar ansiedad, déficit de atención e hiperactividad, trastornos del espectro autista y convulsiones (3, 13).</p>
<p>El fenotipo de los afectados por la MC del gen FMR1 es completamente diferente y no tienen las características clásicas del SXF como discapacidad intelectual (DI) leve a moderada, trastornos del espectro autista, cara alargada, prognatismo, orejas grandes y aladas, articulaciones hiperextensibles, macroorquidismo, déficit del lenguaje, ansiedad y agresión; en mujeres el fenotipo suele ser menos severo <xref ref-type="bibr" rid="B11">11</xref>.</p>
<p>El FXPOI se encuentra en el 20% de las portadoras de la premutación, tienen desaparición de sangrado menstrual por un año antes de los 40 años, lo que hace un diagnóstico de falla ovárica prematura; esta frecuencia esta aumentada 20 veces al compararlo con la población general, en la que la falla ovárica prematura esta alrededor del 1% <xref ref-type="bibr" rid="B14">14</xref> . Además, se ha descrito que la falla ovárica esta aumentada en las portadoras en todas las edades en que se han logrado desarrollar estudios, a los 18 años 1.4%, a los 29 años 3.0% (en la población general 1 en 1,000), y tienen menopausia a más temprana edad después de los 40 años <xref ref-type="bibr" rid="B14">14</xref>. En estas mujeres se encuentran signos y síntomas secundarios como alteración hormonal con niveles de FSH elevados y niveles de estradiol bajos, ciclos menstruales irregulares, síntomas perimenopáusicos y disminución de la reproducción <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>. </p>
<p>En la paciente aquí reportada la asociación de ciclos menstruales irregulares que obligaron a la histerectomía a los 33 años, síntomas vagales (relacionados con menopausia) y el hallazgo de premutación del gen FMR1, nos llevaron a concluir que la paciente tuvo falla ovárica prematura y FXPOI.</p>
<p>El FXTAS es un desorden neurodegenerativo progresivo caracterizado por déficits neurológicos que incluyen temblor progresivo de intención, ataxia cerebelar, déficit cognitivo, parkinsonismo, neuropatías, disfunción autonómica y demencia; este síndrome se presentan en el 40% de los hombres portadores de la premutación a los 60 años y en el 75% a los 80 años, y en el 20% de las mujeres <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B9">9</xref> . En la población general la prevalencia estimada es de 1 en 4,000 hombres después de los 55 años y de 1 en 7,800 en mujeres <xref ref-type="bibr" rid="B3">3</xref></p>
<p>En el FXTAS la alteración en el gen FMR1 no produce el silenciamiento del gen FMR1 como en los afectados por el SXF en quienes la FMRP (Fragile X Mental Retardation Protein) esta disminuida o ausente <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B17">17</xref>, por el contrario hay una sobre expresión, produciendo entre 2-8 veces la cantidad normal de mRNA del FMR1 <xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>, este último sería el responsable de la toxicidad neuronal y llevaría a la presentación tardía de desórdenes neurodegenerativos <xref ref-type="bibr" rid="B4">4</xref>. En el FXPOI no se ha logrado demostrar como la elevación del mRNA afecta el eje hipotálamo-hipófisis-gónada o al ovario directamente <xref ref-type="bibr" rid="B16">16</xref>. </p>
<p>El diagnóstico de FXTAS en portadores de la premutación del gen FMR1 combina criterios clínicos, radiológicos de neuroimágenes y patológicos <xref ref-type="bibr" rid="B12">12</xref>. Los criterios mayores son temblor de intención, ataxia cerebelar, deterioro cognitivo e hiperintensidad del pedúnculo cerebelar medio e inclusiones intranucleares redondeadas típicas de FXTAS en neuronas y astrocitos; los criterios menores incluyen problemas de memoria a corto plazo, de intensidad moderada-severa, neuropatía, déficit en las funciones ejecutivas, parkinsonismo, atrofia cerebral generalizada, enfermedad de la materia blanca en cerebro o en cerebelo. Los síntomas son menos severos en las mujeres <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B18">18</xref>.</p>
<p>Para un diagnóstico definitivo del FXTAS es necesario tener dos criterios mayores: un criterio clínico mayor más uno radiológico mayor o uno patológico; la presencia de dos criterios clínicos mayores o un criterio clínico menor más un criterio radiológico menor hacen un diagnostico probable. Por último un diagnóstico posible de FXTAS se constituye a partir de la presencia de un criterio clínico menor y un criterio clínico menor <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>.</p>
<p>El diagnóstico del FXTAS en la paciente aquí reportada se hizo por tener dos criterios clínicos mayores: temblor de intensión severo y deterioro cognitivo sustentado en un puntaje menor al esperado en el test de MINIMENTAL; y el criterio radiológico menor atrofia cortical generalizada y marcada en la región frontal; además, presentó ansiedad generalizada y neuropatía por síndrome del túnel carpiano. La severidad de los síntomas y la edad temprana aparición del FXTAS hacen que el caso sea poco frecuente y de mal pronóstico.</p>
<p>Sin embargo, en esta paciente la edad de aparición de FXPOI alrededor de los 33 años, la edad de inicio de síntomas del FXTAS antes de los 50 años, la severidad de los síntomas como temblor de intensión que le impide realizar actividades de la vida diaria, temblor mandibular, déficit cognitivo, ansiedad y atrofia cortical generalizada nos hace considerar que se trata de un caso muy poco frecuente, no solo por la baja prevalencia del FXTAS en mujeres, sino también por la escasa presentación de FXTAS y FXPOI simultáneamente, con una historia natural de la enfermedad inusual. </p>
<p>El tratamiento en el FXTAS es principalmente sintomático con opciones terapéuticas que buscan aliviar los síntomas neuromotores y psiquiátricos, siendo los beta bloqueadores, como el propanolol, los más usados para el alivio del temblor esencial, seguidos de los anticonvulsivantes. Pacientes con ataxia han mostrado mejoría con el uso de memantina <xref ref-type="bibr" rid="B19">19</xref>. Los inhibidores selectivos de la recaptación de serotonina (IRSS) indicados en muchos de los trastornos mixtos, asociados a ansiedad o depresión, son de utilidad en los pacientes con FXTAS; así como lo son la actividad física, las actividades lúdicas, el suplemento de folatos y vitamina B12, son usados con el objetivo de mantener las capacidades motoras, cognitivas y disminuir la atrofia cerebral <xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B19">19</xref>. La descripción de las FRAXOPATIAS <xref ref-type="bibr" rid="B4">4</xref> ha sido relativamente reciente y el acceso a pruebas moleculares es limitado en nuestro medio. Sugerimos que en pacientes con falla ovárica prematura, temblor y/o ataxia se debe sospechar que son portadores premutación del gen FMR1, la probabilidad del diagnóstico se aumenta cuando existen antecedentes familiares específicos de SXF o discapacidad intelectual de origen desconocido. También, cuando se encuentran en las imágenes cerebrales los criterios específicos. El diagnóstico se debe descartar o confirmar con pruebas moleculares como PCR y Southern Blot específicos para el gen FMR1 <xref ref-type="bibr" rid="B2">2</xref>.</p>
</sec>
<sec>
<title>Conclusiones</title>
<p>Se aporta un paciente con criterios clínicos y radiológicos de FXTAS y FXPOI con aparición de los síntomas a edad temprana y sintomatología severa, mostrando una historia natural de la enfermedad poco frecuente en portadoras de la premutación del gen FMR1</p>
</sec>
</body>
</sub-article>
</article>
</pmc-articleset>